Predicting risk of breast cancer recurrence using gene-expression profiling

Pharmacogenomics

Volumn 8, Issue 1, 2007, Pages 101-111

  Ignatiadis, Michail ^a   Desmedt, Christine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Gene expression profile; Genomics; Molecular classification; Prediction; Prognosis; Proliferation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; DOCETAXEL; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECISION MAKING; DISEASE FREE SURVIVAL; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MONOTHERAPY; NONHUMAN; PHARMACOGENETICS; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846551711     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.1.101     Document Type: Article

References (53)

1. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
2. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
3. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene-expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
4. Hu Z, Fan C, Oh DS et al.: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
5. Sotiriou C, Neo SY, McShane LM et al.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
6. Andre F, Pusztai L: Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat. Clin. Pract. Oncol. 3, 621-632 (2006).
7. van't Veer LJ, Dai H, van V et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
8. van de Vijver, He YD, van't Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
9. Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
10. Foekens JA, Atkins D, Zhang Y et al.: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
11. Eifel P, Axelson JA, Costa J et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. 93, 979-989 (2001).
12. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21, 3357-3365 (2003).
13. Buyse M, Loi S, Van't VL et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
14. Desmedt C, Piette F, Loi S et al.: Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Late breaking abstact, Fifth European Breast Cancer Conference (2006).
15. Ma XJ, Wang Z, Ryan PD et al.: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
16. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
17. Chang HY, Sneddon JB, Alizadeh AA et al.: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS. Biol. 2, E7 (2004).
18. Chang HY, Nuyten DS, Sneddon JB et al.: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
19. Sotiriou C, Wirapati P, Loi S et al.: Gene-expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006).
20. Sotiriou C, Wirapati P, Loi S et al.: Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer. Proc. Am. Soc. Clin. Oncol. 24, 507 (Abstract) (2006).
21. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-70 (2000).
22. Miller LD, Smeds J, George J et al.: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550-13555 (2005).
23. Sotiriou C, Wirapati P, Loi S et al.: Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. Breast Cancer Res. Treat. - SABCS. (2006).
24. Loi S, Haibe-Kains B, Desmedt C et al.: Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. J. Clin. Oncol. (In press) (2006).
25. Oh DS, Troester MA, Usary J et al.: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. 24, 1656-1664 (2006).
26. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115, 1503-1521 (2005).
27. Kang Y, Siegel PM, Shu W et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
28. Minn AJ, Kang Y, Serganova I et al.: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44-55 (2005).
29. Minn AJ, Gupta GP, Siegel PM et al.: Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
30. Gianni L, Zambetti M, Clark K et al.: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265-7277 (2005).
31. Chang JC, Wooten EC, Tsimelzon A et al.: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23, 1169-1177 (2005).
32. Jansen MP, Foekens JA, Van S, I et al.: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23, 732-740 (2005).
33. Hess KR, Anderson K, Symmans WF et al.: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006).
34. Bild AH, Yao G, Chang JT et al.: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
35. Potti A, Dressman HK, Bild A et al.: Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11), 1294-1300 (2006).
36. Solit DB, Garraway LA, Pratilas CA et al.: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
37. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 22, 207-219 (1992).
38. Olivotto IA, Bajdik CD, Ravdin PM et al.: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23, 2716-2725 (2005).
39. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569-1583 (2005).
40. Desmedt C, Sotiriou C: Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 5 (2006).
41. Braun S, Vogl FD, Naume B et al.: A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
42. Xenidis N, Perraki M, Kafousi M et al.: Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24, 3756-3762 (2006).
43. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
44. Nowell S, Sweeney C, Winters M et al.: Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl Cancer Inst. 94, 1635-1640 (2002).
45. EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
46. Winer EP, Hudis C, Burstein HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
47. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
48. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
49. Citron ML, Berry DA, Cirrincione C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
50. Mamounas EP, Bryant J, Lembersky B et al.: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 23, 3686-3696 (2005).
51. Martin M, Pienkowski T, Mackey J et al.: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302-2313 (2005).
52. Piccart-Gebhart MJ: Anthracyclines and the tailoring of treatment for early breast Cancer. N. Engl. J. Med. 354, 2177-2179 (2006).
53. Pittman J, Huang E, Dressman H et al.: Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc. Natl Acad. Sci. USA 101, 8431-8436 (2004).